ID

17234

Description

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00216099

Link

https://clinicaltrials.gov/show/NCT00216099

Keywords

Versions (1)
  1. 9/1/16 9/1/16 -
Uploaded on

September 1, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT00216099

English

Eligibility Prostate Cancer NCT00216099

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically documented adenocarcinoma of the prostate
Description

adenocarcinoma of prostate

Data type

boolean

Alias
UMLS CUI [1]
C0007112
clinically refractory or resistant to hormone therapy as assessed by progression following at least one hormonal therapy (orchiectomy or luteinizing hormone-releasing hormone (lhrh) agonist)
Description

Clinically refractory or resistant to hormone therapy (orchiectomy or luteinizing hormone-releasing hormone agonist)

Data type

boolean

Alias
UMLS CUI [1,1]
C0205269
UMLS CUI [1,2]
C0029189
UMLS CUI [2,1]
C0205269
UMLS CUI [2,2]
C1518041
one prior taxane based chemotherapy regimen for hrpc
Description

taxane based chemotherapy regimen

Data type

boolean

Alias
UMLS CUI [1]
C0796419
documented progression of disease after one taxane based prior chemotherapy regimen for hrpc. progression is defined as at least one of the following:
Description

Progression of disease

Data type

boolean

Alias
UMLS CUI [1]
C0242656
an increase in psa > 50% over nadir value on prior taxane-based therapy
Description

PSA Measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201544
progression of measurable disease as defined by recist
Description

Recist

Data type

boolean

Alias
UMLS CUI [1]
C1709926
progression of bone disease as defined by the appearance of one or more new bone lesions or worsening symptoms
Description

progression of bone disease

Data type

boolean

Alias
UMLS CUI [1,1]
C0238792
UMLS CUI [1,2]
C0242656
orchiectomy or testosterone levels < 50 ng/dl maintained by lhrh agonist
Description

orchiectomy; testosterone level

Data type

boolean

Alias
UMLS CUI [1]
C0029189
UMLS CUI [2]
C0523912
prior chemotherapy, or other experimental anticancer agents must be completed > 4 weeks prior to being registered for protocol therapy
Description

chemotherapy or other experimental anticancer agents

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0013230
palliative radiotherapy must be completed at least 14 days prior to registration.
Description

Palliative radiotherapy

Data type

boolean

Alias
UMLS CUI [1]
C3898008
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
intravenous radio-isotopes therapy must be completed at least 6 weeks prior to registration
Description

Radioisotope therapy

Data type

boolean

Alias
UMLS CUI [1]
C0203608
no brain metastasis that are untreated and/or not controlled and/or still requiring corticosteroids
Description

Brain metastasis (untreated/uncontrolled/requiring corticosteroids)

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C0332155
UMLS CUI [3,1]
C0220650
UMLS CUI [3,2]
C0001617
no history of other malignancies within 5 years prior to being registered for protocol therapy, except for adequately treated basal or squamous cell skin cancer
Description

Malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
no history of uncontrolled psychiatric illness or serious systemic disease, including active infection, uncontrolled hypertension
Description

Psychiatric illness or serious systemic disease, including active infection, uncontrolled hypertension

Data type

boolean

Alias
UMLS CUI [1]
C0004936
UMLS CUI [2]
C0442893
UMLS CUI [3]
C0009450
UMLS CUI [4]
C1868885
no surgery or significant traumatic injury within 21 days prior to being registered for protocol therapy
Description

Surgery or significant traumatic injury

Data type

boolean

Alias
UMLS CUI [1]
C0543467
UMLS CUI [2]
C3263723
patients must be willing to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8 day period for long acting agents such as piroxicam)
Description

NSAID

Data type

boolean

Alias
UMLS CUI [1]
C0003211
patients must be willing to take folic acid or vitamin b12 supplementation
Description

must be willing to take folic acid or vitamin b12 supplementation

Data type

boolean

Alias
UMLS CUI [1]
C0556110
UMLS CUI [2]
C3661610
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT00216099

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
adenocarcinoma of prostate
Item
histologically documented adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Clinically refractory or resistant to hormone therapy (orchiectomy or luteinizing hormone-releasing hormone agonist)
Item
clinically refractory or resistant to hormone therapy as assessed by progression following at least one hormonal therapy (orchiectomy or luteinizing hormone-releasing hormone (lhrh) agonist)
boolean
C0205269 (UMLS CUI [1,1])
C0029189 (UMLS CUI [1,2])
C0205269 (UMLS CUI [2,1])
C1518041 (UMLS CUI [2,2])
taxane based chemotherapy regimen
Item
one prior taxane based chemotherapy regimen for hrpc
boolean
C0796419 (UMLS CUI [1])
Progression of disease
Item
documented progression of disease after one taxane based prior chemotherapy regimen for hrpc. progression is defined as at least one of the following:
boolean
C0242656 (UMLS CUI [1])
PSA Measurement
Item
an increase in psa > 50% over nadir value on prior taxane-based therapy
boolean
C0201544 (UMLS CUI [1])
Recist
Item
progression of measurable disease as defined by recist
boolean
C1709926 (UMLS CUI [1])
progression of bone disease
Item
progression of bone disease as defined by the appearance of one or more new bone lesions or worsening symptoms
boolean
C0238792 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
orchiectomy; testosterone level
Item
orchiectomy or testosterone levels < 50 ng/dl maintained by lhrh agonist
boolean
C0029189 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
chemotherapy or other experimental anticancer agents
Item
prior chemotherapy, or other experimental anticancer agents must be completed > 4 weeks prior to being registered for protocol therapy
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Palliative radiotherapy
Item
palliative radiotherapy must be completed at least 14 days prior to registration.
boolean
C3898008 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Radioisotope therapy
Item
intravenous radio-isotopes therapy must be completed at least 6 weeks prior to registration
boolean
C0203608 (UMLS CUI [1])
Brain metastasis (untreated/uncontrolled/requiring corticosteroids)
Item
no brain metastasis that are untreated and/or not controlled and/or still requiring corticosteroids
boolean
C0220650 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0332155 (UMLS CUI [2,2])
C0220650 (UMLS CUI [3,1])
C0001617 (UMLS CUI [3,2])
Malignancy
Item
no history of other malignancies within 5 years prior to being registered for protocol therapy, except for adequately treated basal or squamous cell skin cancer
boolean
C0006826 (UMLS CUI [1])
Psychiatric illness or serious systemic disease, including active infection, uncontrolled hypertension
Item
no history of uncontrolled psychiatric illness or serious systemic disease, including active infection, uncontrolled hypertension
boolean
C0004936 (UMLS CUI [1])
C0442893 (UMLS CUI [2])
C0009450 (UMLS CUI [3])
C1868885 (UMLS CUI [4])
Surgery or significant traumatic injury
Item
no surgery or significant traumatic injury within 21 days prior to being registered for protocol therapy
boolean
C0543467 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
NSAID
Item
patients must be willing to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8 day period for long acting agents such as piroxicam)
boolean
C0003211 (UMLS CUI [1])
must be willing to take folic acid or vitamin b12 supplementation
Item
patients must be willing to take folic acid or vitamin b12 supplementation
boolean
C0556110 (UMLS CUI [1])
C3661610 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial